BIOGRAPHICAL SKETCH

NAME: Qijun Wan

POSITION TITLE: Professor

EDUCATION/TRAINING

A.Personal statement

Qijun Wan is a Doctor of Medicine and completed postdoctoral research at Harvard University, and is Director of the renal department at XXX. He is a member of the Standing Committee of the Society of Nephrology of Guangdong Province; a Board Member of the Asia–Pacific Society of Medical Bioimmunity; a Member of the Standing Committee of the Professional Committee of The Society of Medical Bioimmunity; a Member of the Nephrologist Branch of the Guangdong Physicians Association; and Vice Chairman of the Shenzhen Nephrology Society.

Qijun Wan is mainly engaged in basic and clinical research associated with glomerular disease. He is funded by research funds provided by the Guangdong Province and Shenzhen, with the total funding exceeding 300,000 yuan. He has published high-level academic papers in international journals, such as Perit Dial Int as either the first or the corresponding author.

B. Positions and honors

Positions

1989-1993 Resident, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

1996-present Attending Physician, Vice Professor, Professor, The First Affiliated Hospital of Shenzhen University, Shenzhen, China

Honors

None

C. Representative publications (selected publications in recent five years 5-10 publications)

1、Qijun Wan, Yongcheng He, Saodong Luan, et al. Chylous Ascites due to Intravenous Infusion of Long-Chain Fatty Acids [J]. Perit Dial Int, 2013, 33 (3):332-333.

2、Qijun Wan, YongCheng He, Wanfan Zhang, et al. Prevalence and related factors of the absence of anemia among Chinese chronic hemodialysis patients: a multicenter cross sectional study. Int Urol Nephrol, 2013, 45(4):301-304.

3、Qijun Wan, Hao-Fei Hu, Yong-Cheng He, et al. Severe pneumonia in mycophenolate mofetil combined with low-dose corticosteroids-treated patients with IgA nephropathy. Kaohsiung Journal of Medical Science, 2015, 31(1):42:46.

4、Qijun Wan, Hao-Fei Hu, Yong-Cheng He, et al. Tacrolimus combined with low-dose corticosteroids is an effective and safe therapeutic option for refractory Chinese IgA nephropathy. Experimental and Therapeutic Medicine, 2016, 12 (8): 1934-1938.

5、Qijun Wan, Dan Zhu, Ying Liao. A qualitative, enzyme-linked immunospot assay is a promising diagnostic method for tuberculous peritonitis among continuous ambulatory peritoneal dialysis patients: A single-center experience. Biomedical Research. Accepted on October 18, 2017

6、Qijun Wan, Yongcheng He, Minsheng Yuan. Klotho in diabetes and diabetic nephropathy: a brief update review. Int J Clin Exp Med 2017; 10(3):4342-4349.

7、Qijun Wan, Yongcheng He, Hongtao Chen, et al. Is mycophenolate mofetil combined with low-dose 

prednisone a treatment option for advanced IgA nephropathy? A ten-year follow-up case and brief

literature review. European Journal of Inflammation. 2018, volume16:1-4.

8、Ming Ku, Cai Tao, Qi-Jun Wan*. A novel apolipoprotein E mutation (p.Arg150Cys) in a Chinese patient

with lipoprotein glomerulopathy. Chinese Medical Journal 2019;132 (2):237-239 . *Corresponding Author

9、Ricong Xu, Zhijian Li, Qijun Wan*. Serum albumin and tubular interstitial lesions in Chinese patients with IgA nephropathy: A retrospective cohort study. Acta Medica Mediterranea, 2019, 35: 3361 - 3368. *Corresponding Author

D. Research support

1、Shenzhen Science and Technology Bureau foundation（200204056), 2002-2004, Chairmanship

2、Shenzhen Science and Technology Bureau foundation（200602025), 2006-2008, Chairmanship

3、Shenzhen Science and Technology Bureau foundation（201202049), 2012-2014, Chairmanship

4、Shenzhen Science and Technology Commission foundation（JCYJ20130401112724306), 2013-2015, Chairmanship

5、Shenzhen Health and Family Planning Commission foundation （201506033), 2015-2017,

Chairmanship

7、Natural Science Foundation of Guangdong Province (2018A030310648), 2018-202, 2^nd position

Ongoing projects (RMB)

Effect of the proline-rich coiled-coil 2A (PRRC2A) gene on the occurrence of lupus nephritis and its preliminary mechanism （2018A030310648）     01/01/2018 to 12/31/2021

PI: Ricong Xu                                                         ￥100,000